Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Results 1 - 20 of 95 : 1 2 3 4 5 Next »

Recs

0
Member Avatar pchop123 (78.35) Submitted: 4/9/2014 11:53:10 AM : Outperform Start Price: $293.26 BIIB Score: -0.86

Good entry price

Recs

0
Member Avatar 1russianguy (57.26) Submitted: 4/8/2014 3:17:15 PM : Outperform Start Price: $287.06 BIIB Score: +0.95

Sold off too much, play it for a pop.

Recs

0
Member Avatar TSIF (99.96) Submitted: 4/5/2014 2:15:22 PM : Outperform Start Price: $287.49 BIIB Score: +1.92

Much of the biopharms with what appears to be high P/E's are getting rotated out of the past month. I do agree it's hard for biopharms with products to stay ahead of patents, worry about reimbursement rates, etc, to grow forever, but high P/E's usually come from solid growth. Kicking all of the growing Biopharms out because the sector is perceived to be over heating seems like typical all ships up, all ships down.....

Biogen, Idec, Inc is down about 20%, although still up on the year. I had my limit and charting to stay patient for another week or so on this call, with a limit of about $178...but I lost patience watching the tumble and leveling off Friday, (4/4/2014)...redid my chart, drew the line a little differently and decided to take it at $287.

I don't have a clue where bottom is. I only pretend to chart as it helps me define some entry exit points and makes me feel better....
PE of 36 with a forward PE of 20...showing growth needed to support the P/E.

Good margins 25%/35%
Solid YoY 2012-2013 (25%)
But more level QoQ in 2013 with a rise in S&G

I know on a bio that it's about Pipeline, Patents, Sales, etc, and that's harder for a layman to define...so I have to add more weight to financial metrics and "trust" the market more than I would like,

Overall, hard to say where we will retrace, but I believe a few plays of established, growing biopharms, if they dip below my call will rise back into it.....

Recs

0
Member Avatar yooperking (72.16) Submitted: 4/2/2014 10:50:16 AM : Outperform Start Price: $312.75 BIIB Score: -5.39

PEG ratio of 1.5, Quarterly revenue growth (yoy) or 38.6% and Quarterly earnings growth (yoy) of 56.5% makes this company's stock a good buy. Institutional ownership of 94.5%, 0.9% insider ownership and a 1.9 short ratio leaves room for more buyers.

Recs

0
Member Avatar TerryFool (< 20) Submitted: 3/10/2014 8:31:23 PM : Outperform Start Price: $297.84 BIIB Score: -3.30

EPS 1YR 25% 2YR 20% 5YR 18%

Recs

0
Member Avatar RideWildfire (42.04) Submitted: 2/11/2014 11:07:00 AM : Outperform Start Price: $315.77 BIIB Score: -10.61

They are delivering relief to a large population in ways that lead their competitors.

Recs

0
Member Avatar TerryHoodSr (49.05) Submitted: 7/21/2013 1:30:37 AM : Outperform Start Price: $289.85 BIIB Score: +1.42

growth

Recs

0
Member Avatar KimLanners (< 20) Submitted: 6/12/2013 9:18:59 AM : Underperform Start Price: $311.64 BIIB Score: +5.21

Margins are high and up, but once they go down, the valuation should sink dramatacally. I dont see much room

Recs

1
Member Avatar sugarmag23 (< 20) Submitted: 6/5/2013 11:47:30 AM : Outperform Start Price: $215.34 BIIB Score: +20.64

this company will keep coming up with a succession of innovative drugs to treat deadly diseases.

Recs

1
Member Avatar bear713 (< 20) Submitted: 5/22/2013 11:18:31 AM : Outperform Start Price: $236.36 BIIB Score: +12.67

This pharmaceutical company has a well defined niche market and a proven track record of inovation.

Recs

1
Member Avatar elv1659 (37.11) Submitted: 4/9/2013 12:24:42 PM : Outperform Start Price: $192.92 BIIB Score: +32.27

Have a new pill for MS. Before patients had to take infusions. Much easier to administer and control disease.

Recs

1
Member Avatar Phuman2 (< 20) Submitted: 4/9/2013 8:54:25 AM : Outperform Start Price: $194.51 BIIB Score: +30.92

Steady growth and high profit margins

Recs

0
Member Avatar FutureMonkey (84.26) Submitted: 3/2/2013 2:57:41 PM : Outperform Start Price: $167.64 BIIB Score: +51.23

Top 25 pick

Recs

0
Member Avatar 42asdf (49.03) Submitted: 3/1/2013 4:50:40 PM : Outperform Start Price: $167.64 BIIB Score: +51.23

has great growth, profit margins, and financial health. While it's p/e is fairly high (28.9), it is lower than the industry average (45.2).

Recs

0
Member Avatar NHWeston102 (81.88) Submitted: 2/7/2013 11:47:24 AM : Outperform Start Price: $159.11 BIIB Score: +59.16

If you can't develop a ground-breaker, buy one!! Tysabri will do BIIB good!

Recs

0
Member Avatar JorgeAura (< 20) Submitted: 2/2/2013 4:57:02 PM : Underperform Start Price: $156.15 BIIB Score: -62.85

Nasdaq in maximums.

Recs

2
Member Avatar TMFHelical (98.75) Submitted: 11/13/2012 9:54:12 AM : Outperform Start Price: $139.82 BIIB Score: +74.01

One of the leaders of an annual industry audit that looks at value creation in the biotech space.

http://caps.fool.com/Blogs/a-look-at-established-biotech/774287

Recs

1
Member Avatar macginty (< 20) Submitted: 7/30/2011 1:07:51 PM : Outperform Start Price: $105.91 BIIB Score: +132.96

I feel that Tysabri's proven track-record over the past five years, as a prime treatment for multiple sclerosis, is providing real and worthwhile results for a very significant number of people, who must live with this otherwise 'incurable' disease.

Recs

0
Member Avatar TomFoolNC (30.27) Submitted: 5/28/2011 3:35:19 PM : Outperform Start Price: $93.96 BIIB Score: +172.11

new mgt, cutting costs, refocusing investments

Recs

0
Member Avatar EclecticRecluse (78.44) Submitted: 5/5/2011 4:31:17 AM : Outperform Start Price: $95.84 BIIB Score: +165.32

Upward Momentum

Results 1 - 20 of 95 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement